Zhao Yingchao, Jiang Yao
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Onco Targets Ther. 2022 Apr 2;15:323-328. doi: 10.2147/OTT.S362267. eCollection 2022.
Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. The patient received primary cytoreductive surgery with adjuvant chemotherapy and remained disease-free for four months. She then experienced retroperitoneal lymph node recurrence and was treated with liposomal doxorubicin chemotherapy followed by secondary debulking surgery. The patient experienced a second relapse in the lower left lung 11 months later. Genomic profiling of tumor samples revealed a deleterious AT-rich interactive domain 1A () mutation and homologous recombination deficiency. Thus, the triplet combination of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib; the PD-1 inhibitor, pembrolizumab; and the antiangiogenic agent, bevacizumab was administered. The patient achieved partial response, which was sustained for 12 months. Our study provides the first clinical evidence that the combination of olaparib with pembrolizumab and bevacizumab could be an effective treatment for patients with platinum-resistant, recurrent OCCC.
卵巢透明细胞癌（OCCC）是一种侵袭性很强的恶性肿瘤，预后较差，大多数患者在初次治疗后会复发。目前，复发性OCCC尚无标准治疗方案。在此，我们报告一例32岁的OCCC女性患者。该患者接受了初次肿瘤细胞减灭术及辅助化疗，无病生存4个月。随后她出现腹膜后淋巴结复发，接受了脂质体阿霉素化疗，之后进行了二次肿瘤减灭术。11个月后，患者左下肺出现第二次复发。肿瘤样本的基因组分析显示存在有害的富含AT的相互作用结构域1A（）突变和同源重组缺陷。因此，给予了聚（ADP - 核糖）聚合酶（PARP）抑制剂奥拉帕利、PD - 1抑制剂帕博利珠单抗和抗血管生成药物贝伐单抗的三联组合治疗。患者获得部分缓解，且持续了12个月。我们的研究提供了首个临床证据，表明奥拉帕利与帕博利珠单抗和贝伐单抗联合应用可能是铂耐药复发性OCCC患者的有效治疗方法。
